A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis

Launched by SUMITOMO PHARMA AMERICA, INC. · Nov 22, 2019

Keywords

ClinConnect Summary

This clinical trial is investigating a new oral medication called nuvisertib (TP-3654) for patients with myelofibrosis, a type of blood cancer that affects the bone marrow and can lead to severe symptoms. The study aims to understand how safe and effective this drug is, as well as how it works in the body. Patients who might be eligible for the trial are those diagnosed with either primary or secondary myelofibrosis, particularly if they have not responded to previous treatments like JAK inhibitors. To qualify, participants need to meet certain health criteria, including specific blood counts and overall health status.

If you join this trial, you will receive either nuvisertib alone or in combination with other medications, depending on your treatment history. Throughout the study, healthcare professionals will closely monitor your health and any side effects. It's important to know that this trial is currently recruiting participants, and your involvement could provide valuable information about new treatment options for myelofibrosis.

Gender

ALL

Eligibility criteria

• Patients must meet all of the following inclusion criteria to be eligible:
• Nuvisertib (TP-3654) Monotherapy Arm:
• • Confirmed pathological diagnosis of primary myelofibrosis (PMF) or post-PV-MF/post-ET- MF and intermediate or high-risk primary or secondary MF
• • Previously treated with JAK inhibitor(s) and is intolerant, resistant, refractory or has lost response to the JAK inhibitor(s) or is ineligible to be treated with JAK inhibitor
• * Fulfill the following clinical laboratory parameters:
• • Platelet count ≥ 25 x 10\^9 /L, without assistance of growth factors or platelet transfusions
• • ANC ≥ 1 x 10\^9/L without assistance of granulocyte growth factors
• • Peripheral blood blast count \< 5%
• • ECOG performance status ≤ 1
• • Life expectancy ≥ 6 months
• • Adequate renal function
• • Adequate hepatic function
• • Adequate coagulation function
• • Splenomegaly (spleen volume of ≥ 450 cm3 by MRI or CT scan) within 2 weeks prior to Cycle 1 Day 1.
• • Dose escalation: At least 2 symptoms measurable (score ≥ 1) using the MF-SAF
• • Dose expansion: At least 2 symptoms measurable with each score of ≥ 3 or a total average score of ≥ 10 per MFSAF
• Nuvisertib (TP-3654) + Ruxolitinib Arm:
• • Confirmed pathological diagnosis of PMF or post-PV-MF/post ET- MF and intermediate or high-risk primary or secondary MF
• • On ruxolitinib treatment for ≥ 6 months, and on a stable dose of ruxolitinib (5 to 25 mg BID) for ≥ 8 weeks prior to the first dose of nuvisertib, but has either lost response or had a suboptimal or plateau in response
• * Fulfills the following clinical laboratory parameters:
• • Platelet count ≥ 50 × 10\^9/L (without assistance of growth factors or platelet transfusions)
• • ANC ≥ 1 × 109/L without assistance of granulocyte growth factors
• • Peripheral blood blast count \< 5% at screening
• • Adequate renal function
• • Adequate hepatic function
• • Adequate coagulation function
• • Splenomegaly (spleen volume of ≥ 450 cm3 by MRI/CT scan) within 2 weeks prior to Cycle 1 Day 1
• • At least 2 symptoms measurable with each score ≥ 3 or a total average score of ≥ 10 per MFSAF v4.0
• • ECOG performance status ≤ 1
• • Life expectancy ≥ 6 months
• • Nuvisertib (TP-3654) + Momelotinib Arm
• • Confirmed pathological diagnosis of PMF or post-PV-MF/post ET-MF and intermediate or high-risk primary or secondary MF
• • Previously treated with an approved JAK inhibitor (except momelotinib) for PMF or Post-PV/ET MF for ≥ 12 weeks, or ≥ 4 weeks if JAK inhibitor therapy was complicated by a transfusion requirement of ≥ 4 units of red blood cells in 8 weeks, or Grade 3/4 AEs of thrombocytopenia, anemia, or hematoma
• * Fulfills the following clinical laboratory parameters:
• • Anemic, defined as Hb \<10 g/dL or requiring RBC transfusion at baseline
• • Platelet count ≥ 50 × 109/L (without assistance of growth factors or platelet transfusions)
• • ANC ≥ 1 × 109/L without assistance of granulocyte growth factors
• • Peripheral blood blast count \< 5% at screening
• • Adequate renal function
• • Adequate hepatic function
• • Adequate coagulation function
• • Splenomegaly (spleen volume of ≥ 450 cm3 by MRI/CT scan) within 2 weeks prior to Cycle 1 Day 1
• • At least 2 symptoms measurable with each score of ≥ 3 or a total average score of ≥ 10 per MFSAF v4.0
• • ECOG performance status ≤ 1
• • Life expectancy ≥ 6 months
• Patients meeting any one of these exclusion criteria will be prohibited from participating in this study:
• Nuvisertib (TP-3654) Monotherapy Arm:
• • Received previous systemic antineoplastic therapy or any experimental therapy within 2 weeks or 5 half-lives, whichever is longer, prior to Cycle 1 Day 1. Hydroxyurea or anagrelide are allowed up to 24 hours prior to Cycle 1 Day 1).
• • Major surgery within 4 weeks prior to Cycle 1 Day 1 and/or not recovered adequately from from surgery prior to first dose.
• • Splenic irradiation within 6 months prior to Screening or prior splenectomy.
• • Prior allogeneic stem cell transplant within the last 6 months.
• • Eligible for allogeneic bone marrow or stem cell transplantation.
• • Unresolved Grade ≥ 2 non-hematological toxicity related to prior treatment
• • History of symptomatic congestive heart failure, or myocardial infarction, or uncontrolled arrhythmia within 6 months prior to Cycle 1 Day 1; left ventricular ejection fraction (LVEF) \< 45% by echocardiogram within 4 weeks prior to Cycle 1 Day 1.
• • Corrected QT interval \> 480msec.
• • Prior or concurrent malignancy that could interfere with the investigational regime.
• • Known history of chronic liver disease, e.g. portal hypertension or any of its complications, cirrhosis, Child-Pugh C, auto-immune hepatitis, alpha-1 anti-trypsin deficiency, Wilson's disease, etc.
• • Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic antimicrobial within 1 week prior to Cycle 1 Day 1.
• • Chronic active or acute viral hepatitis A, B, or C infection (testing for hepatitis B and C are required)
• • Exhibited allergic reactions or sensitivity to nuvisertib, or similar compound.
• • Medical condition or GI tract surgery that could impair absorption or result in short bowel syndrome with diarrhea.
• • Systemic steroid therapy (\>10 mg daily prednisone or equivalent) within 1 week prior to the first dose of study treatment (note: topical, inhaled, nasal, and ophthalmic steroids are not prohibited).
• • Known clinically significant anemia due to iron, vitamin B12, or folate deficiencies, or autoimmune or hereditary hemolytic anemia, or thalassemia, or severe GI bleeding.
• • Pregnant or breastfeeding
• • Currently receiving any other investigational agent.
• Nuvisertib (TP-3654) + Ruxolitinib Arm:
• • Received previous systemic antineoplastic therapy (other than ruxolitinib) or any other experimental therapy within 2 weeks or 5 half-lives, whichever is longer, prior to Cycle 1 Day 1 (Note: Prior treatment with nuvisertib is not allowed. Hydroxyurea or anagrelide are allowed up to 24 hours prior to Cycle 1 Day 1).
• • Received systemic steroid therapy (\>10 mg daily prednisone or equivalent) within 1 week prior to Cycle 1 Day 1 (Note: Topical, inhaled, nasal, and ophthalmic steroids are not prohibited)
• • Known allergic reactions or sensitivity to nuvisertib, or similar compound.
• • Splenic irradiation within 6 months prior to Screening or prior splenectomy
• • Prior allogeneic stem cell transplant within the last 6 months (Note: Patients who have relapsed after 6 months post-transplant and do not have active GVHD are eligible).
• • Eligible for allogeneic bone marrow or stem cell transplantation (Note: Patients who are not willing to undergo transplantation or for whom a suitable donor is not available are considered as transplant ineligible.)
• • Major surgery within 4 weeks prior to Cycle 1 Day 1 and/or have not recovered adequately prior to first dose.
• • Active, uncontrolled bacterial, viral, or fungal infections, requiring parenteral antimicrobial within 1 week prior to Cycle 1 Day 1
• • Chronic active or acute viral hepatitis A, B, or C infection (testing for hepatitis B and C are required)
• • Known history of chronic liver disease (eg, portal hypertension or any of its complications, cirrhosis, Child-Pugh C, auto-immune hepatitis, alpha-1 anti-trypsin deficiency, Wilson's disease, etc) (Note: Abnormal liver morphology at baseline imaging may require additional testing, as needed).
• • Unresolved Grade ≥ 2 non-hematological adverse events related to prior treatment (stable Grade 2 conditions may be permitted in consultation with the Sponsor)
• • History of myocardial infarction or symptomatic congestive heart failure or uncontrolled arrhythmia within 6 months prior to Cycle 1 Day 1; LVEF \<45% by echocardiogram within 4 weeks prior to Cycle 1 Day 1
• • Corrected QTcF of \> 480 msec
• • Prior or concurrent malignancy that could interfere with the safety or efficacy assessment of the study intervention
• • History of a medical condition or GI tract surgery that could impair absorption or could result in short bowel syndrome with diarrhea
• • Known clinically significant anemia due to iron, vitamin B12, or folate deficiencies, or autoimmune or hereditary hemolytic anemia, or thalassemia, or severe GI bleeding
• • Pregnant or breastfeeding
• Nuvisertib (TP-3654) + Momelotinib Arm:
• • Received previous systemic antineoplastic therapy or any experimental therapy within 2 weeks or 5 half-lives, whichever is longer, prior to Cycle 1 Day 1 (Notes: Prior treatment with momelotinib or nuvisertib is not allowed; in patients with ongoing JAK inhibitor therapy, ie, ruxolitinib, at screening, JAK inhibitor therapy must be tapered over a period of at least 1 week. Patients on a low dose of ruxolitinib (eg, 5 mg QD) may have a reduced taper period or no taper; hydroxyurea or anagrelide are allowed up to 24 hours prior to Cycle 1 Day 1).
• • Received systemic steroid therapy (\>10 mg daily prednisone or equivalent) within 1 week prior to Cycle 1 Day 1 (Note: Topical, inhaled, nasal, and ophthalmic steroids are not prohibited).
• • Known allergic reactions or sensitivity to nuvisertib, momelotinib, or any structurally similar drug, or to any component of the formulations of either study intervention
• • Splenic irradiation within 6 months prior to screening or prior splenectomy
• • Prior allogenic stem cell transplant within the last 6 months (Note: Patients who have relapsed after 6 months post-transplant and do not have active GVHD are eligible).
• • Eligible for allogeneic bone marrow or stem cell transplantation (Note: Patients who are not willing to undergo transplantation or for whom a suitable donor is not available are considered as transplant ineligible).
• • Major surgery within 4 weeks prior to Cycle 1 Day 1 and/or have not recovered adequately from surgery prior to first dose.
• • Active, uncontrolled bacterial, viral, or fungal infections, requiring parenteral antimicrobial within 1 week prior to Cycle 1 Day 1
• • Chronic active or acute viral hepatitis A, B, or C infection (testing for hepatitis B and C are required)
• • Known history of chronic liver disease (eg, portal hypertension or any of its complications, cirrhosis, Child-Pugh C, auto-immune hepatitis, alpha-1 anti-trypsin deficiency, Wilson's disease, etc) (Note: Abnormal liver morphology at baseline imaging may require additional testing, as needed)
• • Unresolved Grade ≥ 2 non-hematological adverse events related to prior treatment (stable Grade 2 conditions may be permitted in consultation with the Sponsor)
• • Presence of Grade ≥ 2 peripheral neuropathy
• • History of myocardial infarction or symptomatic congestive heart failure or uncontrolled arrhythmia within 6 months prior to Cycle 1 Day 1; LVEF \< 45% by echocardiogram within 4 weeks prior to Cycle 1 Day 1
• • Corrected QTcF of \> 480 msec
• • Prior or concurrent malignancy that could interfere with the safety or efficacy assessment of the study intervention
• • History of a medical condition or GI tract surgery that could impair absorption or could result in short bowel syndrome with diarrhea
• • Known clinically significant anemia due to iron, vitamin B12, or folate deficiencies, or autoimmune or hereditary hemolytic anemia, or thalassemia, or severe GI bleeding
• • Pregnant or breastfeeding